DDInter1763 DDInter448
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement. Crizotinib was the first-in-class drug used to treat ALK-positive tumors. Second- and third-generation ALK-tyrosine kinase-inhibitors have overcome many of the pharmacodynamic and genetic resistance mechanisms crizotinib is prone to. Crizotinib was approved by the FDA in 2011, and its use is accompanied by FDA-approved tests used to detect ALK and ROS1 rearrangements.
Temsirolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Crizotinib
Temsirolimus {u} (Compound) upregulates {v} (Gene) IGF1R
IGF1R {u} (Gene) is bound by {v} (Compound) Crizotinib
Temsirolimus {u} (Compound) downregulates {v} (Gene) CASK
CASK {u} (Gene) is bound by {v} (Compound) Crizotinib
Temsirolimus {u} (Compound) upregulates {v} (Gene) COL11A1
COL11A1 {u} (Gene) is upregulated by {v} (Compound) Crizotinib
Temsirolimus {u} (Compound) downregulates {v} (Gene) HMGCS1
HMGCS1 {u} (Gene) is upregulated by {v} (Compound) Crizotinib
Temsirolimus {u} (Compound) downregulates {v} (Gene) ABCE1
ABCE1 {u} (Gene) is downregulated by {v} (Compound) Crizotinib
Temsirolimus {u} (Compound) causes {v} (Side Effect) Fatigue
Fatigue {u} (Side Effect) is caused by {v} (Compound) Crizotinib
Temsirolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Crizotinib
Temsirolimus {u} (Compound) downregulates {v} (Gene) AURKA
AURKA {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is downregulated by {v} (Compound) Crizotinib
Temsirolimus {u} (Compound) upregulates {v} (Gene) IKBKE
IKBKE {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is upregulated by {v} (Compound) Crizotinib
Temsirolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound)
Temsirolimus (Compound) upregulates IGF1R (Gene) and IGF1R (Gene) is bound by Crizotinib (Compound)
Temsirolimus (Compound) downregulates CASK (Gene) and CASK (Gene) is bound by Crizotinib (Compound)
Temsirolimus (Compound) upregulates COL11A1 (Gene) and COL11A1 (Gene) is upregulated by Crizotinib (Compound)
Temsirolimus (Compound) downregulates HMGCS1 (Gene) and HMGCS1 (Gene) is upregulated by Crizotinib (Compound)
Temsirolimus (Compound) downregulates ABCE1 (Gene) and ABCE1 (Gene) is downregulated by Crizotinib (Compound)
Temsirolimus (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Crizotinib (Compound)
Temsirolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Temsirolimus (Compound) downregulates AURKA (Gene) and AURKA (Gene) is bound by Crizotinib (Compound) and AURKA (Gene) is downregulated by Crizotinib (Compound)
Temsirolimus (Compound) upregulates IKBKE (Gene) and IKBKE (Gene) is bound by Crizotinib (Compound) and IKBKE (Gene) is upregulated by Crizotinib (Compound)